Advertisement

Search Results

Advertisement



Your search for all items matches 2968 pages

Showing 1 - 50


breast cancer
cardio-oncology

Case 3: Cardiac Risk Stratification

This is Part 3 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss a challenging...

breast cancer
cardio-oncology

Case 2: CDK4/6 Inhibitor Choice in Medically Fragile Patients With Heart Failure

This is Part 2 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss managing...

breast cancer
cardio-oncology

Case 1: Management of Cardiovascular Risk Factors

This is Part 1 of Managing Cardiovascular Risk in Metastatic Breast Cancer: Clinical Insights on CDK4/6 Inhibitors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Kelly McCann, Hope Rugo, and Avirup Guha discuss cardiovascular ...

hematologic malignancies

Case 3: Patient With Myelofibrosis on Active Treatment

This is Part 3 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of a ...

hematologic malignancies

Case 2: Patient With Myelofibrosis and Anemia

This is Part 2 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of a ...

hematologic malignancies

Case 1: Patient With Newly Diagnosed Post-PV Myelofibrosis

This is Part 1 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of...

multiple myeloma

Case 3: Optimal Sequencing of T-Cell–Redirected Therapies

This is Part 3 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with high-risk...

multiple myeloma

Case 2: Role of T-Cell–Redirected Therapies in Elderly Patients With Relapsed/Refractory Multiple Myeloma

This is Part 2 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with relapsed...

multiple myeloma

Case 1: Role of ASCT in the Era of Quadruplet Induction and T-Cell–Redirected Therapies

This is Part 1 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with newly...

colorectal cancer
genomics/genetics

Clinical Utility of Including ctDNA Monitoring in Standard-of-Care CRC Surveillance

Arvind N. Dasari, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses data presented at the ESMO Gastrointestinal Cancers Congress 2025, which showed that adding circulating tumor DNA (ctDNA) testing to current standard of care surveillance for patients with colorectal cancer...

genomics/genetics

MRD Testing: Recent Data and Ongoing Efforts

Circulating tumor DNA has many roles in cancer treatment: early diagnosis, tumor profiling, determining response to therapy, and tracking clinical dynamics. In this video, Arvind N. Dasari, MD, MS, of The University of Texas MD Anderson Cancer Center, focuses on it as a marker for measurable...

cns cancers

Case 3: High-Grade Astrocytoma

This is Part 3 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade glioma. The...

cns cancers

Case 2: Low-Grade Glioma

This is Part 2 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade glioma. The...

cns cancers

Case 1: Low-Grade Oligodendroglioma

This is Part 1 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade...

hepatobiliary cancer

Case 3: Fibrolamellar Hepatocellular Carcinoma

This is Part 3 of First-Line Systemic Treatment of Advanced Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Laura Goff, Kristen Spencer, and Mark Yarchoan discuss the treatment of fibrolamellar...

hepatobiliary cancer

Case 2: Advanced Hepatocellular Carcinoma

This is Part 2 of First-Line Systemic Treatment of Advanced Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Laura Goff, Kristen Spencer, and Mark Yarchoan discuss the treatment of advanced hepatocellular...

hepatobiliary cancer

Case 1: Metastatic Cholangiocarcinoma

This is Part 1 of First-Line Systemic Treatment of Advanced Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Laura Goff, Kristen Spencer, and Mark Yarchoan discuss the treatment of metastatic...

gynecologic cancers

Case 3: Low-Grade Platinum-Resistant Ovarian Cancer

This is Part 3 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of low-grade platinum-resistant...

gynecologic cancers

Case 2: HER2-Positive Platinum-Resistant Ovarian Cancer

This is Part 2 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of HER2-positive...

gynecologic cancers

Case 1: FRα-Positive, High-Grade, Platinum-Resistant Ovarian Cancer

This is Part 1 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of high-grade platinum-resistant ...

lung cancer

Case 3: Newly Diagnosed Limited-Stage Small Cell Lung Cancer

This is Part 3 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss treatment of newly diagnosed limited-stage small cell ...

lung cancer

Case 2: Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

This is Part 2 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss the treatment of newly diagnosed extensive-stage...

lung cancer

Case 1: Relapsed Small Cell Lung Cancer

This is Part 1 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss the treatment of relapsed small cell lung cancer...

breast cancer

Erika Hamilton, MD, on Oral SERDs in Breast Cancer: State of the Science

Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, provides a look at “where we stand in 2025” in the field of oral selective estrogen receptor degraders (SERDs) for patients with estrogen receptor–positive, HER2-negative breast cancer. She discusses the first...

prostate cancer

Case 3: Recurrent Low-Volume Metastatic Hormone-Sensitive Prostate Cancer

This is Part 3 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the management of recurrent...

prostate cancer

Case 2: High-Risk De Novo Metastatic Hormone-Sensitive Prostate Cancer

This is Part 2 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the treatment of high-risk de...

prostate cancer

Case 1: De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer With PTEN Deficiency

This is Part 1 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the treatment of de novo...

gastrointestinal cancer
neuroendocrine tumors
pancreatic cancer

Case 3: Radioligands in Advanced Neuroendocrine Tumor

This is Part 3 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the use of radioligand therapy for advanced...

neuroendocrine tumors
gastrointestinal cancer

Case 2: Well-Differentiated Grade 3 Small Bowel Neuroendocrine Tumor

This is Part 2 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the treatment of well-differentiated grade 3...

gastrointestinal cancer
neuroendocrine tumors
pancreatic cancer

Case 1: Pancreatic Neuroendocrine Tumor

This is Part 1 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the treatment of pancreatic neuroendocrine...

Case 3: Second-Line Treatment of ER-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 and PIK3CA Mutations

This is Part 3 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 64-year-old postmenopausal woman...

Case 2: Second-Line Treatment of ER-Positive, HER2-Negative Metastatic Breast Cancer and ESR1 D538G Mutation After Progression on CDK4/6 Inhibitor

This is Part 2 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 67-year-old postmenopausal woman...

breast cancer

Case 1: First-Line Treatment of HR-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 Y537S Mutation

This is Part 1 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 61-year-old female patient who...

breast cancer

Case 3: Leptomeningeal Disease in HER2-Positive Breast Cancer

This is Part 3 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a history...

Case 2: Intracranial Progression on ADC Therapy

This is Part 2 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a history...

breast cancer

Case 1: Isolated Brain Relapse in HER2-Positive Breast Cancer

This is Part 1 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a cT2N1,...

hematologic malignancies

Case 3: Managing Myelofibrosis Beyond the First-Line Setting

This is Part 3 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Abdulraheem Yacoub, Gabriela Hobbs, and Douglas Tremblay discuss the treatment of a 70-year-old ...

Case 2: Recognizing Cytopenias and Comorbidities in the First-Line Management of Myelofibrosis

This is Part 2 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.     In this video, Drs. Abdulraheem Yacoub, Gabriela Hobbs, and Douglas Tremblay discuss the treatment of a...

hematologic malignancies

Case 1: Initial Management of a Patient With High-Risk Myelofibrosis

This is Part 1 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Abdulraheem Yacoub, Gabriela Hobbs, and Douglas Tremblay discuss the treatment of a 67-year-old ...

breast cancer

Erika Hamilton, MD, on ER-Positive HER2-Negative Advanced Breast Cancer: Vepdegestrant vs Fulvestrant

Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, reviews data from the global, randomized, phase III VERITAC-2 study, which compared vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor degrader, to fulvestrant among patients with...

prostate cancer

Gerhardt Attard, MD, PhD, on a Novel Regimen for Metastatic Castration-Sensitive Prostate Cancer With HRR Alterations

Gerhardt Attard, MD, PhD, of the Cancer Institute, University College London, presents findings from the phase III AMPLITUDE trial, which looked at the combination of niraparib and abiraterone acetate plus prednisone for patients with metastatic castration-sensitive prostate cancer with alterations ...

Ruben A. Mesa, MD, on Essential Thrombocythemia: SURPASS-ET Trial

Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500). ...

immunotherapy
genomics/genetics

Violaine Randrian, MD, PhD, on Lynch Syndrome, Genetics, and Immunotherapy

Violaine Randrian, MD, PhD, of Memorial Sloan Kettering Cancer Center and CHU/Université de Poitiers, reviews gene-specific outcomes in patients with Lynch syndrome treated with immune checkpoint inhibitors for advanced cancer (Abstract 10504). 

breast cancer

Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy

Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer...

breast cancer
issues in oncology

Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs

Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do...

prostate cancer

Eric Huttenlocher Bent, MD, PhD, on Oligometastatic Prostate Cancer: Intensified Hormonal Blockade

Eric Huttenlocher Bent, MD, PhD, of Memorial Sloan Kettering Cancer Center, reviews results from the phase II Metacure trial (cohorts B2 and the B2 expansion), which looked at the efficacy of stereotactic body radiotherapy for PSMA-PET–detected oligometastatic prostate adenocarcinoma (Abstract...

prostate cancer

Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy

Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013). 

issues in oncology

Suneel Deepak Kamath, MD, on Disparities in NIH and Federal Funding Across Different Cancer Types

Suneel Deepak Kamath, MD, of the Cleveland Clinic, reports findings from a study that evaluated funding from the NIH and Congressionally Directed Medical Research Programs supporting lung, breast, colorectal, pancreatic, hepatobiliary, ovarian, cervical, endometrial, and prostate cancers, as well...

lung cancer

Luis G. Paz-Ares, MD, PhD, on Extensive-Stage SCLC: Comparison of First-Line Regimens

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, discusses data from the TIGOS trial, a phase III study comparing the first-line use of atigotatug (an antifucosyl-GM1 monoclonal antibody) plus nivolumab fixed-dose...

lung cancer

Luis G. Paz-Ares, MD, PhD, on IMforte Trial in Extensive-Stage SCLC

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, presents primary results from the phase III IMforte trial, which evaluated lurbinectedin plus atezolizumab as first-line maintenance treatment in patients with...

Advertisement

Advertisement




Advertisement